INVESTIGATOR'S BIBLIOGRAPHY 
name 
Carlos L. Arteaga, M.D. 
Smith JL, Arteaga C . Heymsfield SB. Increased ureagenesis and impaired nitrogen use during infusion of a synthetic 
amino acid formula. N Engl J Med 306:1013-1018, 1982. 
L. Heymsfield SB, Arteaga C . McManus C, Smith J, Moffitt S. Measurement of muscle mass in humans: Validity of the 
24-hour urinary crea tinine method. Am J ClinNutr 37:478-494, 1983. 
3. Arteaga CL . Clark GM, Von Hoff DD. Laboratory assessment of new approaches to treatment: The human tumor 
cloning system. In: The Management of Bladder Cancer, D. Raghavan (ed), Edward Arnold (Publishers) Ltd, London, 
1988. 
4. Weiss GR, Arteaga CL. Bailes JL, Koeller J, Shenkenberg TD, Von Hoff DD. New anti cancer agents. In; Cancer 
Chemotherapy Annual , HM Pinedo and BA Chabner (eds), Elsevier Science Publishers BV, Amsterdam, 1986. 
5. Weiss GR, Koeller J, Shenkenberg TD, Arteaga CL. Bailes JS, Von Hoff DD. Miscellaneous anti cancer agents. In; 
Cancer Chemotherapy Annual, HM Pinedo and BA Chabner (eds), Elsevier Science Publishers BV, Amsterdam, 1986. 
6. Hanauske A-R, Osborne CK C hamnffs s GC, Clark GM, Force th BJ. Buchok JB. Arteaga CL. Von Hoff DD. Alteration 
of EGF-receptor binding in h uman breast cancer cells by antineoplastic agents. Eur J Clin Oncol 23:505-551, 1987. 
7. Hanauske A-R, Arteaga CL . Clark GM, Buchok JB, Marshall M, Hazarika P, Pardne RL, Von Hoff DD. Determination 
of transforming growth factor activity in effusions from cancer patients. Cancer 61:1832-1837, 1987. 
8. Weiss GR, Arteaga CL. Bailes JL, Koeller J, Shenkenberg TD, Von Hoff DD. New ami cancer agents. In: Cancer 
Pharmacology Annual, BA Chabner and HM Pinedo (eds), Elsevier Science Publishers BV, Amsterdam, 1986. 
9. Weiss GR, Koeller J, Shenkenberg TD, Arteaga CL. Bailes JS, Von Hoff DD. Miscellaneous anticancer agents. In; 
Cancer Pharmacology Annual. BA Chabner HM and Pinedo (eds), Elsevier Science Publishers BV, Amsterdam, 1986. 
10. Arteaga CL . Kisner DL, Goodman A, Von HofF DD*. Eni prininm : A DNA intercalating agent with broad antitumor 
activity in a human tumor clo ning system. Eur J Clin Oncol 23:1621-1626, 1987. 
1 1 . Arteaga CL and Von Hoff DD . Drug selection based on in vitro testing. Im Contemporary Issues in Clinical Oncology: 
Gastric Cancer, HO Douglass (ed), Churchill Livingstone Inc (Publishers), New York, 1988. 
12. Arteaga CL . Hanauske A-R, Clark GM, Osborne CK Hazarika P, Pardue RL, Tio F, Von Hoff DD. Immunn reactive 
alpha transforming growth factor (IraTGF) activity in effusions from cancer patients as a potential marker of tumor 
burden and patient prognosis. Cancer Res 48:5023-5028, 1988. 
Arteaga CL . Forseth B, Clark GM, Von Hoff DD: Radiometric method for chemotherapy sensitivity: Results of 
screening a panel of breast cancer cells lines. Cancer Res 47:6248-6253, 1987. 
14. Weiss GR, Arteaga CL . Brown TD, Craig JB, Harman GS, Koeller JM, Kuhn JG, Von Hoff DD: New anti ca nc er 
agents. In: Cancer Chemotherapy Annual, HM Pinedo and BA Chabner (eds), Elsevier Science Publishers BV, 
Amsterdam, 1987. 
15. Arteaga CL . Tandon AK, Von Hoff DD, Osborne CK Transforming growth factor beta: Potential autocrine growth 
inhibitor of estrogen receptor negative human breast cancer cells. Cancer Res 48:3898-3904, 1988. 
16. Arteaga CL and Clark GM: Inefficacy of mitoguazone in patients with recurrent head and neck squamous cell carcinoma. 
Invest New Drugs 7:281-283, 1989. 
17. Arteaga CL . Coronado EB, Osborne CK Blockade of die epidermal growth factor receptor inhibits transforming growth 
fee tor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol. 
2:1064-1069, 1988. 
18. Arteaga CL . Kitten L, Coronado E, Jacobs S, Knll F, Aired C, Osborne CK Blockade of the type I somatomedin 
receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84: 1418-1423, 1989. 
19. Arteaga CL . Brown T. KnhnJ, Beougfaer K O'RonrkeT, ShenH, Brentzel J. Von Hoff DD. Weiss GR: Phase I c li nical 
and pharmacokinetic trial of Brcquinar Sodium (DUP 785; NSC 368390). Cancer Res 49:4648-4653, 1989. 
20. Arteaga CL and Osborne CK Growth inhibition of human breast cancer cells in vitro with an antibody against the type 
I somatomedin receptor. Cancer Res 49:6237-6242, 1989. 
21. Osborne CK Kitten L, Arteaga CL : Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells 
by anti-estrogens. J Clin Oncol. 7:710-717, 1989. 
22. Weiss GR, Arteaga CL. Brown TD, Craig JB, Hannan GS, Havlin KA, Kuhn JG, Von Hoff DD: New Anticancer 
Agents. In: Cancer Chemotherapy Annual HM Pinedo and BA Chabner (eds), Elsevier Science Publishers BV, 
Amsterdam, 1988. 
23. Osborne CK and Arteaga CL : Autocrine and paracrine growth regulation of breast cancer Clinical implications. Breast 
Cancer Res Treat. 15:3-11, 1989. 
Arteaga CL and Osborne CK Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. 
In: Regulatory Mechanisms in Breast Cancer, ME Lippman and RB Dickson (eds), Kluwer Academic Publishers, Boston, 
1991. 
Recombinant DNA Research, Volume 20 
[189] 
